63 completed, 15 unknown, 7 recruiting, 6 terminated. 31 Phase 4, 24 Phase 3, 19 Phase 2, 10 Not applicable, 7 Phase 1.
Follow Venlafaxine: new trials by email Literature Review of Venlafaxine trials Research Report on Venlafaxine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service TPS-Select, Pharmacologic Pain Management, Interventional Pain Procedures - Postsurgical Pain Management, Postsurgical Pain, Chronic | Phase 3 | Not yet recruiting | University of California, San Francisco | 474 | 2026-10-01 | 2026-10-09 |
| Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure Clozapine, Esketamine Nasal Product, Escitalopram - Schizophrenia and Related Disorders, Major Depressive Disorder | Phase 3 | Recruiting | Dr. Inge Winter | 1254 | 2025-04-27 | 2026-01-22 |
| Effect of Venlafaxine Versus Dosulepin in Pain Predominant Somatic Symptom Disorder Venlafaxine, Dosulepin - Somatic Symptom Disorder (DSM-V) | Phase 4 | Recruiting | All India Institute of Medical Sciences, Bhubaneswar | 84 | 2025-03-11 | 2025-09-24 |
| The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. Escitalopram, Sertraline, Venlafaxine - Bipolar Depression | Phase 3 | Recruiting | Dr. Inge Winter | 418 | 2025-02-11 | 2025-09-26 |
| REDucing Hot FLASHes in Women Using Endocrine Therapy. Oxybutynin, Venlafaxine - Breast Cancer, Hot Flash Due to Medication | Phase 3 | Recruiting | Reinier de Graaf Groep | 260 | 2024-10-03 | 2025-02-04 |
| Mood Disorders in Head and Neck Cancer Patients Venlafaxine - Depressive Disorder, Head and Neck Cancer | Phase 4 | Withdrawn | University of Alabama at Birmingham | 2024-01-05 | 2025-02-04 | |
| A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats Fezolinetant, Paroxetine, Citalopram - Hot Flashes | Completed | Astellas Pharma Global Development, Inc. | 999 | 2023-11-15 | 2026-06-05 | |
| Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer Venlafaxine, Placebo - Head and Neck Cancer, Depression | Phase 2 | Withdrawn | Vanderbilt University Medical Center | 2023-08-01 | 2024-01-18 | |
| Venlafaxine for Postoperative Pain of Laparoscopic Cholecystectomy Venlafaxine, Placebo - Laparoscopic Cholecystectomy | Phase 1 / Phase 2 | Unknown | Mansoura University | 60 | 2023-05-30 | 2023-06-01 |
| Non-interventional, Retrospective Cohort Study to Explore Antidepressant Treatment in Korea Escitalopram, Paroxetine, Fluoxetine - Major Depression | Completed | Pfizer | 370212 | 2022-07-04 | 2024-12-09 | |
| The Role of Negr1 In Modulating Neuroplasticity in Major Depression (RONIN) Venlafaxine - Major Depressive Disorder, Bipolar Affective Disorder, Currently Depressed, Moderate | Phase 4 | Unknown | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | 30 | 2022-03-01 | 2023-11-14 |
| Vortioxetine as a Novel Anti-depressant With Improvement in Cognitive Abilities Vortioxetine, Venlafaxine - Major Depressive Disorder | Phase 3 | Unknown | Scotmann Pharmaceuticals | 500 | 2022-02-01 | 2021-11-18 |
| The Potential Protective Role of Venlafaxine Versus Memantine in Paclitaxel Induced Peripheral Neuropathy Venlafaxine, Memantine - Oncology Pain, Chemotherapy-induced Peripheral Neuropathy | Phase 2 / Phase 3 | Unknown | Mendel AI | 60 | 2021-02-15 | 2021-02-04 |
| Acupuncture for Prophylaxis of Vestibular Migraine Acupuncture, Venlafaxine - Vestibular Migraine | Not applicable | Unknown | Affiliated Hospital of Jiaxing University | 72 | 2021-01-01 | 2020-12-11 |
| Combination Drug-Therapy for Patients With Untreated Obstructive Sleep Apnea Acetazolamide, Eszopiclone, Placebo - OSA, Obstructive Sleep Apnea | Phase 2 | Completed | University of California, San Diego | 20 | 2020-12-01 | 2024-05-29 |
| Pragmatic Trial of Obsessive-compulsive Disorder Sertraline 200 milligram(mg), Sertraline 300 milligram(mg), Fluvoxamine - Obsessive-Compulsive Disorder | Phase 2 | Recruiting | Shanghai Mental Health Center | 1600 | 2020-09-22 | 2025-05-15 |
| Assessing the Efficacy of a Serotonin and Norepinephrine Reuptake Inhibitor for Improving Meniere's Disease Outcomes Venlafaxine, Placebo oral tablet - Meniere Disease | Phase 2 / Phase 3 | Completed | Medical University of South Carolina | 40 | 2020-02-05 | 2024-07-23 |
| Accurate Clinical Study of Medication in Patients With Depression Via Pharmacogenomics (PGx) and Therapeutic Drug Monitoring (TDM) of Venlafaxine pharmacogenomics, pharmacogenomics & therapeutic drug monitoring, Venlafaxine - Depression | Phase 4 | Unknown | Xijing Hospital | 160 | 2019-12-01 | 2019-12-20 |
| Treatment of Withdrawal Symptoms and Prevention of Relapse in Patients With Tramadol Abuse Venlafaxine, Lofexidine - Opiate Withdrawal Syndrome | Phase 4 | Completed | Zagazig University | 52 | 2019-01-01 | 2022-10-06 |
| Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants Tranexamic acid (TXA), labetalol, metformin - Lactating Women on Select DOI, Breastfed Infants of Mothers on Select DOI | Recruiting | Duke University | 1600 | 2018-10-04 | 2026-07-29 |
Showing 20 of 95. Sign in to see all of them.
Depression (32) · Depressive Disorder, Major (22) · Bipolar Disorder (8) · Hot Flashes (8) · Anxiety Disorders (5) · Depressive Disorder (5) · Breast Neoplasms (4) · Cognitive Dysfunction (3) · Dysthymic Disorder (3) · Pain (3) · Alcohol-Related Disorders (2) · Alzheimer Disease (2) · Dementia (2) · Depressive Disorder, Treatment-Resistant (2) · Head and Neck Neoplasms (2)
New York State Psychiatric Institute (5) · Massachusetts General Hospital (3) · Mayo Clinic (3) · University of Pittsburgh (3) · All India Institute of Medical Sciences, Bhubaneswar (2) · Centre for Addiction and Mental Health (2) · Dr. Inge Winter (2) · Eli Lilly and Company (2) · Mansoura University (2) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (2) · Shanghai Mental Health Center (2) · Sumitomo Pharma America, Inc. (2) · University of California, San Diego (2) · University of Pennsylvania (2) · University of Washington (2)
United States (39) · Canada (12) · Germany (8) · China (6) · France (6) · India (4) · Australia (3) · Austria (3) · Belgium (3) · Finland (3) · Italy (3) · Poland (3) · Romania (3) · Taiwan (3) · United Kingdom (3)
Andrea Allen, PhD (1) · Andrew Bishara, MD (1) · Andrew Leuchter, MD (1) · Anurag Singh (1) · Axel Nordenskjold, MD (1) · Bruce G. Pollock, MD, PhD (1) · Changsu Han, MD,PhD, MHS (1) · Chantal Csajka, Prof PhD (1)
PMID 18635722, PMID 21102344, PMID 22249355, PMID 41401709, PMID 11032384, PMID 11522260, PMID 12053639, PMID 16505409, PMID 17173978, PMID 17227907, PMID 17414743, PMID 17474806, PMID 17559726, PMID 18174510, PMID 18227745, PMID 18251622, PMID 18314433, PMID 19081579, PMID 19182688, PMID 19210951, PMID 19223438, PMID 19358791, PMID 19472307, PMID 19485586, PMID 19574030, PMID 19653973, PMID 19730273, PMID 19730274, PMID 19858762, PMID 19963436, PMID 19968380, PMID 20008943, PMID 20478877, PMID 21192150, PMID 21208583, PMID 21334569, PMID 21383263, PMID 21515198, PMID 21784297, PMID 22024002, PMID 22152401, PMID 22251024, PMID 22284022, PMID 22449646, PMID 23158959, PMID 23303421, PMID 23497790, PMID 23582868, PMID 23622849, PMID 23663588
2005 (1), 2023 (1), P50DA009236 (1), R01AA013727 (1), R01AG040093 (1), R01DA015451 (1), R01MH043832 (1), R01MH060353 (1), R01MH061410 (1), R01MH061609 (1), R01MH070919 (1), U01MH061835 (1), U10CA081851 (1), U10MH066750 (1), U10MH066762 (1)